=======Timeline of COVID-19 Vaccines and Treatment======

=====2020=====

//**October 22**// FDA issues Emergency use Authorization (EUA) for Remdesivir in the treatment of patients hospitalized with covid-10 ((https://www.drugs.com/newdrugs/fda-approves-veklury-remdesivir-covid-19-5368.html))

//**November 16**// 
Moderna announces that the interim results of their Covid-19 vaccine candidate Phase III clinical trial have met their primary efficacy endpoint (94.5% (p <0.0001)). 95 participants contracted Covid-19 out of 30,000 participants. ((https://investors.modernatx.com/news/news-details/2020/Modernas-COVID-19-Vaccine-Candidate-Meets-its-Primary-Efficacy-Endpoint-in-the-First-Interim-Analysis-of-the-Phase-3-COVE-Study-11-16-2020/default.aspx))

//**November 18**//
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints. 95% effective against COVID-19 beginning 28 days after the first dose. ((https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine))

//**December 2**//
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19. The Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their COVID-19 mRNA vaccine (BNT162b2).((https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world)) 

//**December 11**//
Pfizer receives an Emergency Use Authorization in the USA for it's Covid-19 vaccine. ((https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization))

//**December 18**//
Moderna receives an Emergency Use Authorization in the USA for it's Covid-19 vaccine. ((https://investors.modernatx.com/news/news-details/2020/Moderna-Announces-FDA-Authorization-of-Moderna-COVID-19-Vaccine-in-U-S--12-18-2020/default.aspx))
===== 2021 =====

{{ :changing_vax_story.mp4 |}}

//**December 09**// US FDA Expands Eligibility for Pfizer-BioNTech COVID-19 Booster Dose to 16- and 17-Year-Olds.((https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-booster-dose-16-and-17))

//**October 29**// US FDA Authorizes COVID-19 Vaccine in Children 5 through 11. ((https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age))

//**September 22 **// US FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Those Older than 65 and those at High Risk for Sever Covid-19.((https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations))

//**August 12**// US FDA Authorizes Booster Dose for Immunocompromised People((https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised))

//**May 10**// US FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents age 12-15.((https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use))

//**April 23 **// USA FDA and CDC Lift the Safety Pause on the Johnson & Johnson (Janssen) COVID-19 Vaccine.((https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough))

//**April 13 **// U.S. CDC and FDA recommend a pause on the Johnson & Johnson (Janssen) vaccine due to 6 cases cerebral venous sinus thrombosis (CVST).((https://www.fda.gov/news-events/press-announcements/joint-cdc-and-fda-statement-johnson-johnson-covid-19-vaccine))

//**February 27 **// US FDA issues an emergency use authorization (EUA) for the Janssen COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older. ((https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine))

//**February 9 **// FDA issued an EUA for emergency use of bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.  ((https://www.fda.gov/media/145801/download))
===== 2022 =====

//**January 3**//
FDA expands Pfizer-BioNTech COVID-19 Vaccine EUA to include the use of a single booster dose in children 12 through 15 years of age; shorten the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least five months, and allow for a third primary series dose for certain immunocompromised children 5 through 11 years of age.((https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine))

//**January 21**//
FDA expands indication for Remdesivir to non-hospitalized adults with Covid-19 ((https://www.drugs.com/newdrugs/fda-approves-veklury-remdesivir-non-hospitalized-patients-risk-covid-19-progression-5772.html))

//**April 25**//
FDA approves Remdesivir for treatment of pediatric patients under 12 years of age with Covid-19 ((https://www.drugs.com/newdrugs/veklury-remdesivir-first-only-approved-pediatric-patients-under-12-years-age-covid-19-5820.html))

//**July 13**//
FDA issues EUA for the Novavax vaccine in people aged 18 and over ((https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-emergency-use-novavax-covid-19-vaccine-adjuvanted))